The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286. The planned total duration of the trial is approximately 100 weeks.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
200
administered orally
Number of participants experiencing an adverse event
Time frame: Baseline to Week 100
Number of participants who withdrew from the trial due to an adverse event
Time frame: Baseline to Week 100
Number of participants with potentially clinically significant vital sign values
Time frame: Baseline to Week 96
Number of participants with potentially clinically significant laboratory test values (hematology and chemistry)
Time frame: Baseline to Week 96
Number of participants with potentially clinically significant 12-lead ECG measurements
Time frame: Baseline to Week 96
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Teva Investigational Site 15554
La Jolla, California, United States
RECRUITINGTeva Investigational Site 15544
Boca Raton, Florida, United States
RECRUITINGTeva Investigational Site 15555
Tampa, Florida, United States
RECRUITINGTeva Investigational Site 15546
Kansas City, Kansas, United States
RECRUITINGTeva Investigational Site 15549
New York, New York, United States
RECRUITINGTeva Investigational Site 15551
New York, New York, United States
RECRUITINGTeva Investigational Site 15548
Pittsburgh, Pennsylvania, United States
RECRUITINGTeva Investigational Site 15543
Spokane, Washington, United States
RECRUITINGTeva Investigational Site 35290
Bordeaux, France
RECRUITINGTeva Investigational Site 35289
Marseille, France
NOT_YET_RECRUITING...and 26 more locations